Accueil>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Calcium Channel>>β-Amino Acid Imagabalin Hydrochloride (PD-0332334)

β-Amino Acid Imagabalin Hydrochloride (PD-0332334) (Synonyms: PD-0332334)

Catalog No.GC31248

β-Amino Acid Imagabalin Hydrochloride (PD-0332334) (PD-0332334) est un ligand pour le α2δ sous-unité du canal calcique voltage-dépendant.

Products are for research use only. Not for human use. We do not sell to patients.

β-Amino Acid Imagabalin Hydrochloride (PD-0332334) Chemical Structure

Cas No.: 610300-00-0

Taille Prix Stock Qté
1mg
1 324,00 $US
En stock
5mg
2 979,00 $US
En stock
10mg
5 066,00 $US
En stock
20mg
8 935,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

β-Amino Acid Imagabalin Hydrochloride (PD-0332334) is a ligand for the α2δ subunit of the voltage-dependent calcium channel.

β-Amino Acid Imagabalin Hydrochloride had been in phase III clinical trials for the treatment of generalised anxiety disorders. However, this research has been discontinued[2]. β-Amino Acid Imagabalin Hydrochloride had been also in phase I clinical trials for the treatment of chronic kidney disease[3].

[1]. Birch M, et al. A Simplified Process for the Manufacture of Imagabalin Hydrochloride (PD-0332334), an α2δ-Ligand for the Treatment of Generalised Anxiety Disorder. Org. Process Res. Dev., 2011, 15 (6), pp 1358-1364

Avis

Review for β-Amino Acid Imagabalin Hydrochloride (PD-0332334)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for β-Amino Acid Imagabalin Hydrochloride (PD-0332334)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.